030CF1C8-2006-4620-B6BE-68A2CC2A0F05
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 46.846254927726676
- age_years
- 36
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.361
- MYC_TARGETS_V1+0.358
- TGF_BETA_SIGNALING+0.348
- MYC_TARGETS_V2+0.298
- G2M_CHECKPOINT+0.296
- NOTCH_SIGNALING+0.275
- DNA_REPAIR+0.234
- E2F_TARGETS+0.225
- IL6_JAK_STAT3_SIGNALING+0.181
- UNFOLDED_PROTEIN_RESPONSE+0.165
Top 10 suppressed
- MYOGENESIS-0.371
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.307
- OXIDATIVE_PHOSPHORYLATION-0.280
- KRAS_SIGNALING_DN-0.262
- MTORC1_SIGNALING-0.250
- FATTY_ACID_METABOLISM-0.240
- BILE_ACID_METABOLISM-0.214
- UV_RESPONSE_UP-0.201
- ADIPOGENESIS-0.198
- CHOLESTEROL_HOMEOSTASIS-0.182
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934988 | — | — | 0.817 |
| 2 | 1AF24109-5FE4-4868-ADB9-5DFDB57BCA0F | — | — | 0.816 |
| 3 | 3AD94D09-83F9-4E15-946F-1123E468F582 | — | — | 0.813 |
| 4 | 3CFE193B-09B3-4038-AA66-156BEEA28DDC | — | — | 0.805 |
| 5 | SRR934806 | — | — | 0.797 |
| 6 | 8B2B5542-3E54-4643-BB57-0BEFCF89A16B | — | — | 0.793 |
| 7 | SRR934847 | — | — | 0.787 |
| 8 | 694B3BE3-104F-4D90-8733-4E99230EFAC6 | — | — | 0.786 |
| 9 | D902E43A-F384-432A-B690-D20BFCC78443 | — | — | 0.773 |
| 10 | SRR934900 | — | — | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.361 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.358 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.348 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.298 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.296 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.275 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.234 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.225 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.181 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.165 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.157 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.154 | Inavolisib | — uncovered |
| APOPTOSIS | 0.124 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.102 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.098 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.095 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.022 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.008 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.004 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.003 | Inavolisib | — uncovered |